Skip to main content

Table 2 Use of anti-malarial drugs during pregnancy

From: Timing of intermittent preventive treatment for malaria during pregnancy and the implications of current policy on early uptake in north-east Tanzania

District Pangani Tanga Korogwe TOTAL
Facility level District Hospital Dispensary District Hospital Health Centre District Hospital Dispensary  
Respondents per facility 17 13 32 28 19 10 119
Any anti-malarials taken during this pregnancy        
   As treatment, n (%) 3 (17.7) 2 (15.4) 8 (25.0) 5 (17.9) 4 (21.1) 1 (10.0) 23 (19.3)
   As prevention, n (%) 12 (70.6) 9 (69.2) 12 (37.5) 14 (50.0) 11 (57.9) 9 (90.0) 67 (56.3)
Heard of IPTp, n (%) 14 (82.4) 11 (84.6) 19 (59.4) 24 (85.7) 18 (94.7) 10 (100) 96 (80.7)
Received any doses IPTp        
   Overall, n (%) 9 (52.9) 7 (53.9) 11 (34.4) 15 (53.6) 14 (73.7) 9 (90.0%) 65 (54.6)
   Uptake among those ≥ 5 months gestation* 64.3% 77.8% 40.0% 62.5% 100% 100% 67.0%
Received ≥ 2 doses IPTp        
   Overall, n (%) 7 (41.2) 5 (38.5) 4 (12.5) 5 (17.9) 6 (31.6) 4 (40.0) 31 (26.1)
   Uptake among those ≥ 7 months gestation** 87.5% 75.0% 16.7% 30.8% 85.7% 66.7% 48.2%
  1. Respondents who had not heard of IPTp were not asked about doses received
  2. *Denominator is number of respondents who were 5 months gestation or later
  3. **Denominator is number of respondents who were 7 months gestation or later